Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.96 |
| ▸ | MEN1 | O00255 | 8/20 | 0.96 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.96 |
| ▸ | TDP1 | Q9NUW8 | 7/20 | 0.96 |
| ▸ | HSP90AA1 | P07900 | 6/20 | 0.96 |
| ▸ | HTT | P42858 | 6/20 | 0.96 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.96 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.96 |
| ▸ | LMNA | P02545 | 5/20 | 0.96 |
| ▸ | TP53 | P04637 | 4/20 | 0.96 |
| ▸ | USP2 | O75604 | 3/20 | 0.96 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.96 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.96 |
| ▸ | HPGD | P15428 | 2/20 | 0.96 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.96 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.96 |
| ▸ | EGFR | P00533 | 1/20 | 0.96 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.96 |
| ▸ | LCK | P06239 | 1/20 | 0.96 |
| ▸ | FYN | P06241 | 1/20 | 0.96 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Iodoquinol SCHEMBL3460 | 0.98 | KDM4E (1.00) | KDM4EMEN1KMT2ATDP1HSP90AA1 | |
| Iodoquinol SCHEMBL29606817 | 0.98 | KDM4E (1.00) | KDM4EMEN1KMT2ATDP1HSP90AA1 | |
| Iodoquinol SCHEMBL29367180 | 0.98 | KDM4E (1.00) | KDM4EMEN1KMT2ATDP1HSP90AA1 | |
| Iodoquinol SCHEMBL28519246 | 0.96 | KDM4E (0.96) | KDM4EMEN1KMT2ATDP1HSP90AA1 | |
| Iodoquinol SCHEMBL28518289 | 0.96 | KDM4E (0.96) | KDM4EMEN1KMT2ATDP1HSP90AA1 | |
| Iodoquinol SCHEMBL28536045 | 0.96 | KDM4E (0.96) | KDM4EMEN1KMT2ATDP1HSP90AA1 | |
| Chloroxine SCHEMBL29157288 | 0.86 | KDM4E (0.80) | KDM4EMEN1KMT2ATDP1HSP90AA1 | |
| Iodoquinol SCHEMBL7520643 | 0.86 | KDM4E (0.77) | KDM4EMEN1KMT2ATDP1HSP90AA1 | |
| SCHEMBL29154096 | 0.85 | KDM4E (0.77) | KDM4EMEN1KMT2ATDP1HSP90AA1 | |
| Clioquinol SCHEMBL27671588 | 0.84 | KDM4E (0.97) | KDM4EMEN1KMT2ATDP1HSP90AA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110257146-A1 | Method of Treating Kcnq Related Disorders Using Organozinc Compounds | THE JOHNS HOPKINS UNIVERSITY (US) | 2011-10-20 | — | — | US | claimed |
| WO-2007087424-A2 | METHOD OF TREATING KCNQ RELATED DISORDERS USING ORGANOZINC COMPOUNDS | THE JOHNS HOPKINS UNIVERSITY (US) | 2007-08-02 | — | — | WO | claimed |
| EP-1377300-A1 | ZINC IONOPHORES AS ANTI-STRESS AGENTS | Fliss, Henry (CA) | 2004-01-07 | — | — | EP | claimed |
| US-20020183300-A1 | Zinc ionophores as anti-stress agents | ZINC THERAPEUTICS CANADA, INC. (CA) | 2002-12-05 | — | — | US | claimed |
| WO-2002080943-A1 | ZINC IONOPHORES AS ANTI-STRESS AGENTS | FLISS HENRY (CA) | 2002-10-17 | — | — | WO | claimed |
| WO-2024054807-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND TDP-43 MODULATORS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-14 | — | — | WO | disclosed |
| WO-2024054811-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-14 | — | — | WO | disclosed |
| WO-2024050389-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND NMDA RECEPTOR ANTAGONISTS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-07 | — | — | WO | disclosed |
| CN-111937886-A | Preparation of 8-hydroxyquinoline complex and application thereof in preventing and treating plant diseases | 兰州大学 | 2020-11-17 | — | — | CN | disclosed |
| US-20110257146-A1 | Method of Treating Kcnq Related Disorders Using Organozinc Compounds | THE JOHNS HOPKINS UNIVERSITY (US) | 2011-10-20 | — | — | US | disclosed |
| WO-2007087424-A2 | METHOD OF TREATING KCNQ RELATED DISORDERS USING ORGANOZINC COMPOUNDS | THE JOHNS HOPKINS UNIVERSITY (US) | 2007-08-02 | — | — | WO | disclosed |
| US-20040167114-A1 | Zinc ionophores as therapeutic agents | FLISS HENRY (CA) | 2004-08-26 | — | — | US | disclosed |
| US-6689774-B2 | TREATING APOPTOSIS. ESPECIALLY BY ADMINISTERING ZINC PYRITHIONE, HETEROCYCLIC AMINES, DITHIOCARBAMATES AND VITAMINS. | ZINC THERAPEUTICS, CANADA INC. (CA) | 2004-02-10 | — | — | US | disclosed |
| US-20030119805-A1 | Zinc ionophores as therapeutic agents | FLISS HENRY (CA) | 2003-06-26 | — | — | US | disclosed |
| US-6495538-B2 | APOPTOSIS THERAPY | ZINC THERAPEUTICS, CANADA INC. (CA) | 2002-12-17 | — | — | US | disclosed |
| US-20010036939-A1 | Zinc ionophores as therapeutic agents | ZINC THERAPEUTICS, CANADA INC. (CA) | 2001-11-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110257146-A1 | Method of Treating Kcnq Related Disorders Using Organozinc Compounds | KCNQ3, KCNQ1, KCNQ5 | KDM4E 488/4885MEN1 774/4885KMT2A 154/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.